1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment

After The Post-Pandemic Sell-Off, Investors Could Be Returning To The Sector

 
• By Andy Smith

Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

In the year to the start of second-quarter earnings season, the broad US S&P 500 stock index had risen by nearly 19%. This was partly driven by big technology companies and partly by multiple expansion resulting from investors’ hopes that falling inflation will increase company profits. A notable absentee from this party was the pharmaceutical sector, with the NYSE Arca Pharmaceutical Index (DRG) falling by nearly 2%, while healthcare conglomerate Johnson & Johnson’s (J&J’s) stock price lagged both these indexes with a fall by nearly 10% over the same period.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.